

REMARKS

This submission is in response to the Official Action dated June 16, 2003. Claims 3 and 4 have been canceled, without prejudice or disclaimer. Claim 14 has been allowed. Claims 14 and 15 have been amended. Claims 14 and 15 are pending and at issue. Reconsideration of the above identified application, in view of the above amendments and the following remarks, is respectfully requested.

Claim 14, allowed by the Examiner in the June 16, 2003 Official Action, has been amended to independent form. Claim 15 has been amended to depend from claim 14.

No new matter has been added by way of this amendment.

Enablement

Claims 3, 4, and 15 stand rejected as allegedly not enabled by the specification.

With this submission, claims 3 and 4 have been canceled, without prejudice or disclaimer. It is therefore believed that the rejection as applied to claims 3 and 4 is moot.

Since the Office Action did not set forth any specific reason as to why claim 15 was included in the rejection, the undersigned assumes that claim 15 was

{M:\1034\1F811\00053789.DOC [REDACTED] }

included in the rejection because of its dependency from claim 3. As amended, claim 15 now depends from allowed claim 14. Further, the specification clearly enables a method of inducing cellular extensions by contacting nerve cells with a hNPRAP having the sequence of SEQ ID NO:14 in an amount effective to cause cellular extensions, wherein the cellular extensions terminate upon distantly located cells. See, e.g., the specification at page 4, lines 11-13:

Applicant has now discovered that over-expression of hNPRAP, ... , causes the development of numerous long, dendritic processes which typically terminate upon distantly located cells.

Accordingly, it is respectfully submitted that this rejection has been overcome and should be withdrawn.

*

*


*

In view of the above amendments and remarks, it is respectfully requested that the application be reconsidered and that all pending claims be allowed and the case passed to issue.


{M:\1034\1F811\00053789.DOC [REDACTED] }

If there are any other issues remaining which the Examiner believes could be resolved through either a Supplemental Response or an Examiner's Amendment, the Examiner is respectfully requested to contact the undersigned at the telephone number indicated below.

Respectfully submitted,


Anna Löqvist, Ph.D.
Limited Recognition Under 37 C.F.R.
10.9(b) (see attached)
Representative for Applicants

DARBY & DARBY, P.C.
Post Office Box 5257
New York, NY 10150-5257
Phone (212) 527-7700

{M:\1034\1F811\00053789.DOC  }

Serial No. 09/501,171
Response to Office Action dated June 16, 2003

Docket No. 01034/100F811-US1
Page 5